Ferro Hugo H, Juni Mariana, Bello Ricardo, Vidal Alejandro, Diez Roberto A, Pavlovsky Santiago
Bio Sidus S.A., Constitución 4234, 1254 Buenos Aires, Argentina.
Transfus Apher Sci. 2009 Oct;41(2):87-93. doi: 10.1016/j.transci.2009.07.007. Epub 2009 Aug 20.
To describe utilization of a biosimilar product containing filgrastim (Neutromax), data of 414 myeloma or lymphoma patients subjected to autologous SCT between 1998 and 2007 were analyzed. Filgrastim was used for mobilization of progenitors (5 days at 300 microg/day) and for the recovery of neutropenia after transplantation (100 microg/day, since day +5). In 2003, the excipient mannitol was replaced by sorbitol. A mean dose of 9.47 x 10(6)CD34(+)cells/kg was infused; 100 neutrophils/mm(3) required 5-day treatment; 500 neutrophils/mm(3), 6 days and 1000 neutrophils/mm(3), 7 days. Neutromax effect in SCT is similar to reports with other brands. No difference was found between formulations.
为描述含非格司亭（Neutromax）的生物类似药产品的使用情况，分析了1998年至2007年间414例接受自体造血干细胞移植的骨髓瘤或淋巴瘤患者的数据。非格司亭用于动员祖细胞（300微克/天，共5天）以及移植后中性粒细胞减少的恢复（自第+5天起，100微克/天）。2003年，辅料甘露醇被山梨醇取代。平均输注剂量为9.47×10⁶个CD34⁺细胞/千克；中性粒细胞计数达100/立方毫米需要5天治疗；中性粒细胞计数达500/立方毫米需要6天；中性粒细胞计数达1000/立方毫米需要7天。Neutromax在造血干细胞移植中的效果与其他品牌的报道相似。不同配方之间未发现差异。
